Bio-Techne Introduces ProximityScope™ Assay Revolutionizing Spatial Biology
Bio-Techne Corporation (NASDAQ: TECH), a leader in life science tools and reagents, has launched its highly anticipated ProximityScope™ assay. This innovative technology is designed for seamless integration with the BOND RX staining platform from Leica Biosystems. With this advancement, researchers can now visualize functional protein-protein interactions within fixed tissues at subcellular resolution, significantly enhancing spatial biology research.
Visualizing Protein-Protein Interactions
The ProximityScope assay is built to provide clear visual signals that indicate when two proteins of interest come into physical proximity. This capability opens up new avenues for understanding complex biological mechanisms that were previously difficult to assess. Working alongside the BOND RX platform, this assay also pairs exceptionally well with ACD's RNAscope Multiomic LS kit, allowing for simultaneous detection of protein and RNA within the same tissue section.
Enhancing Research with Automation
“Integrating our ProximityScope with the BOND RX platform represents a significant milestone in advancing spatial biology,” stated Karan Arora, Senior Vice President of Advanced Assays at Leica Biosystems. The automation provided by this collaboration delivers the scalability and consistency researchers require to explore intricate protein-protein interactions effectively.
Precision and Specificity for Better Outcomes
Conventional methods for studying protein interactions often fall short, lacking the necessary localization data or requiring cells to be dissociated, which can obscure spatial orientation. The ProximityScope assay addresses these issues by offering high sensitivity, specificity, and minimal background interference, ensuring high confidence in the results.
Applications in Health and Disease
Key applications for this innovative assay include several areas of research such as visualizing cell-cell interactions, which can be crucial for studying immune checkpoints or bispecific antibodies. Furthermore, it aids in analyzing cell surface interactions that activate signaling pathways, evaluating therapeutic antibodies for safety and specificity, and investigating interactions that drive transcriptional processes.
Showcasing at National Event
This revolutionary automated multiomic workflow will be highlighted at a prominent meeting of the Society for Immunotherapy of Cancer (SITC) event scheduled for November. Attendees are encouraged to visit Booth 603 to learn more about the capabilities and applications of the ProximityScope assay.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is an influential life sciences company that develops groundbreaking tools and bioactive reagents for both the research and clinical diagnostic sectors. Their diverse product portfolio, featuring hundreds of thousands of items, aids scientists in their investigations into biological processes and is crucial for refining clinical diagnostics. In the most recent fiscal year, Bio-Techne reported over $1.2 billion in sales and maintains a workforce of approximately 3,100 employees globally.
About Leica Biosystems
Leica Biosystems is recognized as a leader in cancer diagnostics, providing comprehensive solutions essential for the pathology workflow. Dedicated to advancing cancer diagnostics, Leica’s products range from sample preparation and staining to imaging and analysis, ensuring a streamlined process from biopsy to diagnosis. As a subsidiary of Danaher Corporation, Leica Biosystems is committed to improving lives through superior diagnostic innovations.
Frequently Asked Questions
What is the ProximityScope™ assay?
The ProximityScope™ assay is a new technology by Bio-Techne that visualizes protein-protein interactions within fixed tissue at a subcellular level.
How does the ProximityScope™ work?
It works by providing a clear visual signal when two proteins are in close physical proximity, revealing insights into biological mechanisms.
What are the primary benefits of using the ProximityScope™?
The primary benefits include high sensitivity and specificity, minimal background noise, and the ability to visualize interactions without losing cellular context.
Where will the ProximityScope™ be displayed?
It will be featured at the upcoming Society for Immunotherapy of Cancer (SITC) meeting.
Who partners with Bio-Techne for the ProximityScope™?
Bio-Techne has partnered with Leica Biosystems for the development and automation of the ProximityScope assay on the BOND RX platform.
